Tendonitis Treatment Market Size, Share and Global Trend By Type (Achilles Tendonitis, Supraspinatus Tendonitis, Tennis or Golfers Elbow, De Quervains Tenosynovitis, Others), By Treatment (Drugs, Devices), and Regional Forecast, 2024-2032

Tendonitis is referred to as an acute condition when the tendons (a flexible but inelastic cord of tissue connecting the bone to muscle) gets inflamed or irritated. This inflammation from tendonitis can cause several problems such as decreased muscle strength from where the tendon arises, mobility loss and pain. Some of the symptoms associated with tendonitis include tenderness, frozen shoulder and mild swelling.

Tendonitis occurs in some parts in an individual such as knees, elbows, heels, shoulders, the base of thumbs, Achilles tendon and wrists. The common names for some of the types of tendonitis include swimmer’s shoulder, golfer's elbow, tennis elbow and jumper's knee. The causes of tendonitis include sudden injuries due to exercise or occupational work, but individuals at risk of being diagnosed include the aging individuals, especially the individuals involved in sports. Tendonitis requires proper treatment, as with the absence of proper treatment, it may lead to tendon ruptures and a condition called tendinosis, a degenerative condition.

The global tendonitis treatment market is anticipated to grow owing to several factors such as the increasing incidence of tendonitis, aging population, demand for preventive care, increasing healthcare expenditure, increasing awareness, effective and quick treatments, increase in competitive sports & recreational sports, and introduction of new treatments. According to the U.S. Bureau of Labor Statistics, tendonitis leads to almost 70,000 cases of individuals missing their work annually.

In a 2018 study published by professors of sports medicine of University of Virginia & Duke University, 40% to 50% of competitive runners suffer from Achilles tendinopathy and the incidence of tendonitis in the general population was approximately 5-10 per 100,000, which is significantly higher in competitive sports.

The factors limiting the growth of the global tendonitis treatment market include the recurrent nature of the injuries, ineffective and less prompt treatments, and the associated side effects of the treatments.

Key Players Covered

Some of the major companies that are present in the global tendonitis treatment market are Abbott, Pfizer Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc and Merck & Co., Inc.

SEGMENTATION

Based on treatment, the devices segment is estimated to have a larger portion of the global tendonitis treatment market during the forecast duration due to the increased demand for the devices. In January 2015, Integra LifeSciences Corporation released Integra Reinforcement Matrix, an implant made from porcine dermis, indicated for use in tendon injuries requiring surgical interventions. This is likely to favour the devices segment in the global tendonitis treatment market.

Key Insights

• Prevalence of tendonitis for key countries
• Regulatory scenario for key countries
• New Product Launch
• Recent industry developments such as partnerships, mergers, and acquisitions

Regional Analysis

North America dominates the global tendonitis treatment market due to a number of factors such as strategic collaboration between pharmaceutical companies, increase in government aided research grants, and rapid adoption for advanced treatment methods. In Europe, the global tendonitis treatment market is expected to expand in the forecast duration due to the increasing prevalence of tendonitis & sports injuries and emerging government guidelines for the treatment of tendonitis. Asia Pacific is projected to register remarkable growth in the global tendonitis treatment market owing to the growing aging population pool and improving health infrastructure.

Key Industry Developments

• In January 2015, Integra LifeSciences Corporation released Integra Reinforcement Matrix, an implant made from porcine dermis, indicated for use in tendon injuries requiring surgical interventions.
• In March 2017, RepliCel Life Sciences completed the phase I human clinical study of RCT-01, a cell therapy for the treatment of patients with injured Achilles tendon
• MiMedx is conducting phase 3 clinical trial on Micronized dHACM Injection which can be used for treating patients having Achilles Tendonitis